TY - JOUR
T1 - Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes
T2 - A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
AU - Leiter, Lawrence A.
AU - Bain, Stephen C.
AU - Hramiak, Irene
AU - Jódar, Esteban
AU - Madsbad, Sten
AU - Gondolf, Theis
AU - Hansen, Thomas
AU - Holst, Ingrid
AU - Lingvay, Ildiko
N1 - Funding Information:
This study was supported by Novo Nordisk A/S, Denmark. The funding sources contributed to the design and conduct of the trial, the analysis and interpretation of the data, review and approval of the manuscript.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/6/6
Y1 - 2019/6/6
N2 - Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are important considerations for further study. Methods: Subjects were grouped according to gender, age (50-65 years and > 65 years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate change from baseline in HbA1c and body weight, as well as tolerability. Results: A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were > 65 years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). Revascularizations, HbA1c and body weight were also reduced consistently across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders. Conclusions: In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile.
AB - Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are important considerations for further study. Methods: Subjects were grouped according to gender, age (50-65 years and > 65 years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate change from baseline in HbA1c and body weight, as well as tolerability. Results: A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were > 65 years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). Revascularizations, HbA1c and body weight were also reduced consistently across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders. Conclusions: In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile.
KW - Age
KW - Baseline cardiovascular risk
KW - Cardiovascular events
KW - Cardiovascular outcome trial
KW - Gender
KW - SUSTAIN 6
KW - Semaglutide
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85066867301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066867301&partnerID=8YFLogxK
U2 - 10.1186/s12933-019-0871-8
DO - 10.1186/s12933-019-0871-8
M3 - Article
C2 - 31167654
AN - SCOPUS:85066867301
SN - 1475-2840
VL - 18
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 73
ER -